MetaCap

Beam Therapeutics (BEAM) vs Lycia Therapeutics (LYCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Beam Therapeutics is the larger company by market cap ($2.16 billion vs $1.72 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAM-13.10%LYCA+10.23%
+22%+2%-18%
Oct 23, 20261 yearNov 20, 2026
BEAM-13.10%LYCA+10.23%
+15%+0%-14%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAM versus LYCA key metrics
MetricBEAMLYCA
Share price$20.90$33.07
Market cap$2.16B$1.72B
1-day change-0.19%+4.09%
YTD return-24.60%—
1-year return-5.90%—
5-year return-73.44%—
EPS (TTM)$-0.87$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$139.74M—
Revenue growth (YoY)+120.01%—
Net income (latest FY)$-79.99M—
Operating margin-274.57%—
Net margin-57.24%—
52-week high$38.26$36.49
52-week low$20.44$22.19
Distance from 52-week high-45.37%-9.37%
Analyst consensusstrong_buy—
Avg. price target upside+138.52%—
Average volume2.04M432.72K
Shares outstanding103.50M52.09M
Employees55731
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Beam Therapeutics

BEAM stock →

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

BEAM vs LYCA FAQ

Which is bigger, Beam Therapeutics or Lycia Therapeutics?

Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.16B compared with $1.72B for Lycia Therapeutics (LYCA).

Are Beam Therapeutics and Lycia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons